Table 3 Clinical significance of miRNA application in the cancer therapy response
From: The potential of microRNAs in cancer diagnostic and therapeutic strategies: a narrative review
Cancer type | miR(s) studied | Role | Method | Key findings | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|
Prostate cancer | miR profiles in the blood | Predicting treatment resistance | Not provided | Resistance to metastatic castration-resistant prostate cancer therapy | NCT04662996 |
Prostate cancer | Exosomal miRs | Predicting the efficacy of androgen deprivation | RNA sequencing | Correlation with the response to androgen deprivation therapy | NCT02366494 |
Colon cancer (Stage II) | miR-21, miR-20a-5p, miR-103a-3p, miR-106b-5p, miR-143-5p, and miR-215 | Characterization of patients undergoing adjuvant chemotherapy | qRT-PCR | Provide information about the adjuvant chemotherapy response | NCT02466113 |
Non-small-cell lung cancer | Plasma miRs | Evaluate the response to anti-PD-1/PD-L1 treatment | Not provided | Correlation with immunotherapy response | NCT04427475 |
Triple negative breast cancer | Serum miR profiles | Determine the levels in patients undergoing chemotherapy | Not provided | Correlation with the chemotherapy response | NCT04771871 (Phase 2) |
Prostate cancer (low-risk) | miR-141, miR-375 | Correlation with focal brachytherapy response | Not provided | Predicting the response to focal brachytherapy | NCT02391051 (Phase 2) |